Core Insights - Aspen Neuroscience has successfully closed a Series C funding round, raising $115 million to advance the clinical development of its lead autologous cell therapy candidate, ANPD001, for moderate-to-advanced Parkinson's disease [1] - The funding will also enhance the company's manufacturing capabilities and support additional therapies in its pipeline [1] Funding Details - The Series C round was co-led by OrbiMed, Frazier Life Sciences, ARCH Venture Partners, and Revelation Partners, with participation from existing investors such as Medical Excellence Capital, Axon Ventures, S32, LifeForce Capital, and LYFE Capital [2] - New investors include Gilead's Kite, Balyasny Asset Management, Cormorant Asset Management, and Prebys Ventures, bringing the total funds raised by Aspen to over $340 million, which includes an $8 million grant from the California Institute for Regenerative Medicine (CIRM) [2] Use of Funds - The funds will be allocated to advancing the company's pipeline of autologous induced pluripotent stem cell (iPSC)-derived therapies targeting additional neurological conditions [3] - Aspen's manufacturing platform utilizes machine learning and genomics to create personalized cells for individual patients [3] Clinical Development Progress - The financing follows the initiation of dosing for the Phase I/IIa Cohort three commercial formulation and the presentation of six-month efficacy and safety data for Cohort one [4] - ANPD001 has received fast-track designation from the US Food and Drug Administration [4] Leadership and Strategic Vision - Aspen Neuroscience's CEO, Damien McDevitt, expressed gratitude for the confidence shown by investors, emphasizing the importance of their experience and capital resources in advancing clinical development and commercial readiness [5] - The strategic guidance and financial support from the investor syndicate will enable Aspen to scale operations, expand its pipeline, and bring transformative therapies closer to patients in need [5]